key: cord-1042942-1aft4ouq
authors: Song, Jia; Deng, Yi-ke; Wang, Hai; Wang, Zhi-chao; Liao, Bo; Ma, Jin; He, Chao; Pan, Li; Liu, Yang; Alobid, Isam; Wang, De-yun; Zeng, Ming; Mullol, Joaquim; Liu, Zheng
title: Self-reported Taste and Smell Disorders in Patients with COVID-19: Distinct Features in China
date: 2021-02-13
journal: Curr Med Sci
DOI: 10.1007/s11596-021-2312-7
sha: 492e08531d1985675b6c1e8106d04ea1bf0105c8
doc_id: 1042942
cord_uid: 1aft4ouq

Last December 2019, a cluster of viral pneumonia cases identified as coronavirus disease 2019 (COVID-19) was reported in Wuhan, China. We aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss of smell and taste, as well as their presentation as the first symptom of the disease and their association with the severity of COVID-19. In this retrospective study, 1206 laboratory-confirmed COVID-19 patients were included and followed up by telephone one month after discharged from Tongji Hospital, Wuhan. Demographic data, laboratory values, comorbidities, symptoms, and numerical rating scale scores (0–10) of nasal symptoms were extracted from the hospital medical records, and confirmed or reevaluated by the telephone follow-up. From patients (n=1172) completing follow-up, 199 (17%) subjects had severe COVID-19 and 342 (29.2%) reported nasal symptoms. 20.6% COVID-19 patients had loss of taste (median score=6), while 11.4% had loss of smell (median score=5). Loss of taste scores, but not loss of smell scores, were significantly increased in severe vs. non-severe COVID-19 patients. Interleukin (IL)-6 and lactose dehydrogenase (LDH) serum levels were positively correlated with loss of taste scores. About 80% of COVID-19 patients recovered from smell and taste dysfunction in 2 weeks. In this cohort, only 1 out of 10 hospital admitted patients had loss of smell while 1 out of 5 reported loss of taste which was associated to severity of COVID-19. Most patients recovered smell and taste dysfunctions in 2 weeks. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available for this article at 10.1007/s11596-021-2312-7 and is accessible for authorized users.

serve as an early alerting symptom for COVID-19 [5] . However, an early study based on analyzing electronic medical records of 214 patients with COVID-19 in Wuhan, China reported that the proportion of patients complaining of loss of taste and loss of smell was only 5.6% and 5.1%, respectively [6] , significantly lower than that reported in Europe and USA. One potential reason for the low rates in China may be related to incomplete medical records of COVID-19 patients under actual emergency situation, which underestimated the incidences of upper airway tract manifestations. Nevertheless, it is also possible that there are different responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with distinct ethnic/culture background. Therefore, more accurate evaluation of upper airway tract manifestations in COVID-19 patients should be conducted to figure out the clinical importance of smell and taste dysfunction in the early diagnosis of COVID-19 for Chinese and to elucidate whether there are different clinical manifestations between patients with distinct ethnic/culture background. Moreover, several important questions remain to be answered. How severe are the upper airway tract symptoms in patients with COVID-19? Is there any correlation between olfactory and taste disorders and other nasal symptoms such as nasal obstruction? Will the severity of olfactory or taste disorder be associated with the severity of COVID-19? Will there be a full recovery of olfactory or taste disorder and how long it will take?

In this retrospective study, we investigated the COVID-19 patients discharged from Tongji Hospital, the largest designated hospital to treat patients with COVID-19, in Wuhan. By integrating medical record analysis and reevaluation of upper airway symptoms via the telephone follow-up, we aimed to explore the frequencies of nasal symptoms in patients with COVID-19, including loss of smell and taste, as well as their presentation as the first symptom of the disease and their association with the severity of COVID-19.

A single center, retrospective cohort study was conducted in Wuhan, China. We obtained the electronic medical records for discharged COVID-19 patients between January 27, 2020 and March 10, 2020, who were initially admitted to Tongji Hospital. The diagnosis was made on the basis of guidance for diagnosis and management of COVID-19 released by WHO [7] . A laboratory-confirmed case of COVID-19 was defined as having positive result on real-time reverse-transcriptase-polymerase-chain-reaction assay of nasal and pharyngeal swab specimens. Only laboratory-confirmed cases were included in the study.

All patients were followed up by telephone on the 30th (±2) day after discharge. The study was approved by Tongji Hospital Research Ethics Committee.

The degree of severity of COVID-19 was defined as severe and non-severe at the time of admission using the American Thoracic Society guidelines for community-acquired pneumonia [8] . The information of demographic characteristics, systemic major symptoms, and major commodities related to COVID-19 were extracted from electronic medical records. In addition, the results of laboratory assessments on admission were also collected from electronic medical records. All laboratory testing was performed according to the clinical care needs of the patients. Laboratory assessments consisted of a complete blood routine, blood biochemistry, coagulation function, infection biomarkers and immune function. All data were entered into a computerized database and cross-checked.

The airway comorbidities and nasal symptoms, the date of symptomatic onset, and numerical rating scale scores and duration days of symptoms were obtained based on the hospital medical records and were confirmed and reevaluated by the telephone followup. The severity of upper respiratory tract symptoms was scored by patients on a numerical rating scale of 0-10, with 0 being "no complaint whatsoever" and 10 being "the worst imaginable complaint" [9, 10] . Six major symptoms of upper respiratory tract were focused on: nasal obstruction, rhinorrhea, nasal itching, sneezing, loss of smell, and loss of taste. The severity of loss of smell and loss of taste was defined as follows: mild=score 0-3; moderate=score 4-7; severe=score 8-10 [9, 10] . The difference between the symptom of loss of smell and loss of taste was explained to the patients very carefully during telephone follow-up according to previous studies [11] . The detailed questionnaire is shown in this article's Online Supplement.

For continuous variables, Kruskal-Wallis H test was used to assess intergroup variability and Mann-Whitney U 2-tailed test was used for between-group comparison. Chi-square test was applied to compare the difference in proportions between groups. Spearman test was used for correlation analysis. Difference was considered to be statistically significant if a P value was less than 0.05. These statistical analyses were performed by an IBM SPSS 22.0 package (SPSS Inc, USA).

Totally 1206 patients were enrolled and 1172 of them completed questionnaires. The follow-up rate was Of the 1172 cases, 399 (25.1%) had at least one comorbidity, and 17.3% had one or more respiratory comorbidities, including allergic rhinitis (AR, 9.8%), chronic rhinosinusitis (CRS, 6.1%), asthma (2.5%) and chronic obstructive pulmonary disease (COPD, 0.9%). The frequency of patients with at least one nasal symptom was up to 29.2%, including nasal obstruction (8.6%; median score, 3), rhinorrhea (10.3%; median score, 3), nasal itching (4.9%; median score, 2), sneezing (11.0%; median score, 2), loss of smell (11.4%; median score, 5), and loss of taste (20.6%; median score, 6). The incidence of symptom reported as the first onset symptom was <1% for each individual nasal symptom, including loss of smell and taste. No significant difference in frequency of patients with loss of smell or taste disorder was found between severe and non-severe COVID-19 cases ( fig. 1A ). The scores of loss of taste but not smell were significantly higher in the patients with severe than in non-severe COVID-19 [7 (5-9) vs. 6 (4-8); P=0.03)] ( fig. 1B ). No significant difference in frequency or score for the other nasal symptoms was found between severe and non-severe disease.

Senses of smell and taste are determined by the chemosensory system of the upper respiratory tract, which could be impacted by the nasal dysfunction [11] . Hence, we analyzed the relations between the scores of loss of taste and smell and other nasal symptoms. We failed to find any correlation between loss of taste or loss of smell scores and scores of the other nasal symptoms ( Given the possibility that some patients might not well distinguish the taste and smell disorder [11] , we compared the differences among the patients only with one smell or taste disorders, the patients with both smell and taste disorders, and the patients without any of these two symptoms. We found that the patients without loss of smell and taste were significantly elder than the patients in the other two groups [62 (48-69) years vs. 59 (46-67) years, 57.5 (42.75-66) years, P=0.03)]. No difference in other clinical characteristics and laboratory measurements was found among three groups. The data are shown in table E1 in the Online Supplement.

We found that 82.1% (110/134) of patients with loss of sense of smell and 95.5% (231/242) of patients with loss of taste recovered in one month after discharge. The symptomatic duration days showed no 1D ). No significant difference in recovery frequency of smell function was found between severe (83.3%) and non-severe cases (81.8%) (P=0.99) (table 1). As to taste disorder, 95.3% patients with severe COVID-19 and 95.5% patients with non-severe COVID-19 recovered, and no significant difference was showed neither (P=0.99) (table 1). Due to the limited number of patients with un-recovered symptoms, we did not compare the differences between recovered and un-recovered patients with loss of smell or loss of taste.

Since the taste disorder is one of the most common upper respiratory tract symptoms and shows a positive correlation with the symptom of loss of smell, we subsequently compared the differences among the COVID-19 patients with different severity of loss of taste (table 2) and loss of smell (table 3) . First, we divided 242 cases of COVID-19 with loss of taste into mild (score, 1-3; 19.0%), moderate (score, 4-7; 48.8%) and severe (score, 8-10; 32.2%) groups according to symptom scores, similar to the visual analogue scale system of nasal symptoms [10] . More COVID-19 cases with severe illness were found in the severe loss of . 2 ). In addition, serum levels of interleukin-6 (IL-6) and lactate dehydrogenase (LDH) were significantly increased in patients with severe vs. mild and moderate loss of taste groups (table 2). Levels of IL-8 were significantly increased in severe and moderate loss of taste group compared to mild group (table 2). The characteristics of the patients with different severity of taste disorder are shown in table 2. In addition, IL-6 and LDH showed a mild positive correlation to the symptom scores of loss of taste (ρ=0.15, P=0.03; ρ=0.21, P<0.01, respectively; fig. 3 ).

As to the comparison among different severity of loss of smell, we divided the 134 patients with loss of sense of smell into mild (score, 1-3, 23.9%), moderate (score, 4-7; 35.8%) and severe (score, 8-10; 40.3%) groups. No significant difference in clinical and laboratory measurements was found among the patients with different severity (table 3 and fig. 2 ).

Overall, 17% subjects were categorized as severe COVID-19, this percentage being similar with previous reports from China [1, 6] . Most of the common systemic signs and symptoms of disease such as fever, fatigue, and anorexia, etc. reported in previous studies were also observed in our cohort [1, 6] . Nevertheless, under urgent admission of COVID-19 patients, compared to systemic symptoms and comorbidities, nasal symptoms and upper airway comorbidities were very likely incompletely documented and underestimated in previous studies based on medical record analysis [1, 12] . In order to overcome this limitation in real-world setting, we did recalled questionnaires by phone call to reevaluate the presence of airway comorbidities, and frequency and severity of nasal symptoms. As a result, the frequencies of COVID-19 patients with AR and CRS were 9.8% and 6.1%, respectively. Previous studies have reported that the incidence of adult AR and CRS in general population in China was 17.6% and 8%, respectively, higher than that reported for COVID-19 [13, 14] . Recent studies indicate that the increasing eosinophils may be an indicator of COVID-19 improvement [15] . Hence, we cannot rule out the possibility that the comorbidities of allergic and eosinophilic diseases such as AR might be potential protective factors for severe COVID-19.

Here, we found that upper respiratory tract symptoms were identified in 29.2% patients with COVID-19, with nasal obstruction, rhinorrhea, nasal itching and sneezing presenting in mild/moderate severity and loss of smell and taste presenting in moderate/severe severity. All of these upper respiratory tract symptoms have been commonly reported in other respiratory viral infection, such as influenza and rhinovirus [16] . Our data suggest that similar with the common respiratory viruses, SARS-CoV-2 may be able to infect upper respiratory tract mucosa and cause similar symptoms [11, 17, 18] . In addition, the result in our Wuhan cohort revealed that the self-reported symptoms of upper respiratory tract were not the first symptom in most COVID-19 patients, doubting the diagnostic value of these symptoms preceding the onset of full-blown clinical disease. However, our study only included hospitalized COVID-19 patients while the clinical manifestations of COVID-19 can range from asymptomatic infection to severe pneumonia [1] . Further investigations on non-hospitalized infected patients and patients with likely sudden onset anosmia will help to determine the role of upper airway symptoms, particular loss of smell and taste, as a screening tool for COVID-19.

Interestingly, the loss of taste and smell was the most common upper respiratory tract symptoms observed in COVID-19 patients in Wuhan, with 17.5% patients having only smell or taste disorder and 7.3% patients having both symptoms. By integrating medical record analysis and follow-up confirmation and reevaluation after discharge, we reported higher rates of smell and taste disorder in the hospitalized patients than an early report from Wuhan, which relied on medical record analysis only and had a smaller sample size [6] . However, the rates of smell and taste disorder in our cohort were significantly lower than those reported in Europe and America [2] [3] [4] [5] 19] . It may be related to the different characteristics of COVID-19 patients. In our study, asymptomatic patients and non-hospitalized patients with mild symptoms were not included. It is also likely that people with distinct ethnic/culture background may have different responses to SARS-CoV-2 infection. Previously, no large-sample-size investigation of olfactory and taste disorders in the disease caused by either SARS-CoV-1 or middle east respiratory syndrome coronavirus, that belongs to the same family of coronaviruses, was undertaken. A case report revealed the olfactory disorder in a patient infected with SARS-CoV-1 [20] . Nevertheless, olfactory and taste disorders are well known to be widely associated with a number of viral infections [21, 22] . The frequency of patients with loss of smell in the present study was similar to that of post-viral olfactory dysfunction (PVOD) caused by the common respiratory virus, such as influenza with a rate of about 17% [17, 18] . PVOD can be caused by mechanical obstruction of odorant transmission due to edema of nasal mucosa, and/or the inflammatory impairment of the olfactory neuroepithelium and even central nervous systems [11, 17, 23] . Recent studies indicated that the dysfunctions of smell and taste in COVID-19 patients may share several potential mechanisms with the PVOD caused by the common respiratory virus, Severity of self-reported loss of taste was scored by patients on a numerical rating scale of 0-10, with 0 being "no complaint whatsoever" and 10 being "the worst imaginable complaint" such as the inflammation and damage of the olfactory epithelium [24] [25] [26] . However, the pathogenesis of the SARS-CoV-2-induced chemosensory dysfunctions needs to be elucidated. We found that the scores of taste and smell dysfunction showed no correlation with the scores of the other nasal symptoms including nasal obstruction, disfavoring a role of mechanical obstruction in the dysfunction of smell and taste. In fact, the symptom scores indicate that COVID-19 patients suffer from mild/moderate nasal obstruction and rhinorrhea, despite moderate/severe olfactory and taste disorder. SARS-CoV-1 has demonstrated a transneural penetration through the olfactory bulb in mice model [27] . Angiotensin converting enzyme 2, which is used by SARS-CoV-1 and SARS-CoV-2 to invade the host cells, is widely expressed on the epithelial cells in nasal and oral cavity [28, 29] . This evidence suggests a neurological involvement in smell and taste disorder caused by SARS-CoV-2 infection. In this study, COVID-19 patients with severe illness had more severe taste disorder. In addition, serum levels of IL-6, a pro-inflammatory cytokine, were elevated in patients with severe taste disorder, and positively correlated with the loss of taste scores. Previous studies demonstrated that the pro-inflammatory cytokines were able to impair the function of taste buds directly, thus leading to taste dysfunction [30, 31] . The present study revealed that 95.5% patients with loss of taste and 82.1% patients with loss of smell recovered spontaneously, and most of them in 2-week time, although the severe impairment of olfactory and smell function may lead to delayed recovery. The spontaneous recovery may be a result of regeneration of the damaged olfactory epithelium and taste buds [32] . Previously, oral and topical corticosteroids have been proposed to treat viral-associated olfactory loss. However, systemic corticosteroids may impair the viral clearance. Given to the high rate of spontaneous recovery of olfactory and taste function, it seems that there is no need to use corticosteroids for treating olfactory and smell disorder in patients with COVID-19, although their administration can be continued to treat comorbidities such as AR and CRS [33] .

We have to acknowledge that there are several limitations of this study. First, the self-reported and recalled symptoms and comorbidities without diagnostic testing, especially for the symptomatic information of loss of smell and taste obtained over a month after onset, might contribute to under-or overestimation of the prevalence of these symptoms, and the strength of association with the clinical outcomes. Second, the self-report and questionnaire-based evaluation could not clearly discriminate the symptoms of loss of smell and taste in patients with COVID-19. It is the inherent limitation of the study based on selfreported data. Third, it was impossible to include the fatal cases due to the incomplete medical records regarding upper airway symptoms and comorbidities, and impossible telephone recall. Fourth, asymptomatic patients and non-hospitalized patients with mild symptoms were missed in this study. Fifth, we cannot preclude the influence of AR and CRS comorbidity on the presentation of upper airway symptoms during COVID-19. However, most of our patients claimed that their primary AR or CRS was under control at baseline and we found no difference in upper airway symptoms between patients with and without AR or CRS comorbidity (data not shown).

Clinical Characteristics of Coronavirus Disease 2019 in China

Self-reported Olfactory and Taste Disorders in Patients with Severe Acute Respiratory Coronavirus 2 Infection: A Crosssectional Study

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

Smell and taste symptom-based predictive model for COVID-19 diagnosis

Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease

Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

European Position Paper on Rhinosinusitis and Nasal Polyps Current

Comparison of efficacy of fluticasone propionate versus clarithromycin for postoperative treatment of different phenotypic chronic rhinosinusitis: a randomized controlled trial

Investigation of chemosensitivity during and after an acute cold

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis

Epidemiology of chronic rhinosinusitis: results from a cross-sectional survey in seven Chinese cities

Dysregulation of Immune Response in Patients with Coronavirus

Detection of Parainfluenza Virus 3 in Turbinate Epithelial Cells of Postviral Olfactory Dysfunction Patients

Identification of Viruses in Patients with Postviral Olfactory Dysfunction. The Laryngoscope

Clinical Features of Respiratory Viral Infections Among Inpatients at a Major US Tertiary Care Hospital

Olfactory and Gustatory Dysfunction in Coronavirus Disease 2019 (COVID-19)

Olfactory neuropathy in severe acute respiratory syndrome: report of A case

Smell and taste disorders

The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries

Anosmia in COVID-19: Underlying Mechanisms and Assessment of an Olfactory Route to Brain Infection

COVID-19 and the Chemical Senses: Supporting Players Take Center Stage

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV

Inflammatory stimuli acutely modulate peripheral taste function

Interleukin 6 in Hyposmia

A primer on viralassociated olfactory loss in the era of COVID-19

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement

We thank to Cai-lin CHEN, Zhao-qin LIAN, Mengchen WANG, Jing-xian LI, Jing-xin LIU, Qiao XIAO, Si-tao HU, Chong-shu WANG, Yi-bo LIU, Jian-wen RUAN and Xue-li LI for their help with data collecting.

The authors declare that they have no competing interests.